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INTRODUCTION 
BOTULINUM TOXIN IN DERMATOLOGY 
Justinus Kernerfirst described botulinum toxin as a "sausage 
poison" and "fatty poison",[1] because the bacterium that produces the 
toxin often caused poisoning by growing in improperly prepared meat 
products. Kerner, a physician, first conceived a possible therapeutic use 
of botulinum toxin and coined the name botulism (from Latinbotulus - 
meaning "sausage").  
In 1897, Emile van Ermengem found that the organism producing 
botulin toxin was a bacterium, which he named Clostridium botulinum.[2] 
In 1928, P. Tessmer Snipe and Hermann Sommer were the first to 
purify the toxin.[3] 
In 1949, Arnold Burgen's et al discovered, through an elegant 
experiment, that botulinum toxin blocks neuromuscular transmission by 
decreasingacetylcholine release.[4] 
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Botulinum finds several application in the field of dermatology as 
follows : 
• Treatment of hyperhidrosis – axillary, palmar and plantar 
hyperhidrosis, gustatory sweating syndrome. 
• Aesthetic dermatology – facial wrinkles. 
• For skin tightening effect as is observed with meso-therapy 
  
3 
 
 
 
 
FIGURE 1 – 3D STRUCTURE OF BOTULINUM TOXIN 
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AIM OF THE STUDY 
1. To study the effectiveness of botulinum toxin in palmar  
hyperhidrosis and dynamic facial wrinkles. 
2. To analyse the safety and tolerability profile of it among the 
patients treated with it. 
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REVIEW OF LITERATURE 
Various strains of the bacterium Clostridium botulinum produce, 
seven distinct serotypes of botulinum toxin (BTX) which includes A, B, 
C1, D, E, F and G all capable of affecting neural function [5]. Although all 
these serotypes produce chemical denervation resulting in atrophy of 
skeletal muscles by blocking acetylcholine (Ach) release from motor 
neurons at the neuromuscular junction (Fig. 2 ), they differ with regard to 
cellular mechanism of action and clinical profile [6]. 
BTX specifically inhibits acetylcholine release by cleaving proteins 
in the SNARE complex (required for Ach release) 
BTX-Aacts by cleaving SNAP-25 (synaptosome associated 
protein), key protein for successful docking and release of Ach from 
vesicles within nerve endings. 
BTX-B cleaves synaptobrevin or VAMP (vesicle associated 
membrane protein). 
 
 
 FIGURE 2 – MOA 
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OF BOTULINUM TOXIN 
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BTX type A (BTX-A) was the serotype first developed for clinical 
use. Neuronox® (South Korea) is the brand available in India and used in 
this study.  
Intramuscular injections of BTX-A have become the treatment of 
choice for a number of disorders characterized by muscular hyperactivity, 
such as strabismus[6], blepharospasm and hemifacial spasm[7], and 
cervical dystonia[8]. In addition, the ability of BTX to stop acetylcholine 
release from autonomic nerve endings supplying glandular tissue or 
smooth muscle has led to investigation of its use for other indications, 
including hyperhidrosis [9], migraine [10], tension headaches [11] and 
myofascial pain [12].  
The only other available serotype is a formulation of BTX type B 
that was approved in the US by the Food and Drug Administration (FDA) 
in 2000 for the treatment of cervical dystonia, but has been used off-label 
to treat facial wrinkles and evaluated in several smaller clinical trials[15–
17]. Research indicates that there are key differences in effects between 
BTX-A and BTX-B for the treatment of facial wrinkles - BTX-B has a 
more rapid onset of action but a shorter duration of effect, diffuses more 
widely, and is associated with greater pain and other side effects than 
BTX-A[18,19]. 
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DILUTION AND HANDLING OF BOTULINUM TOXIN  
Neuronox®is available as a lyophilised powder with 
approximately 50 U or 100 U per vial. The manufacturers recommend 
that the products be reconstituted with sterile, non-preserved saline. Data 
suggests that reconstitution with preserved saline may not alter the 
stability of BTX-A[20,21] and helps in considerable reduction of pain on 
injection[22]. For these reasons, preserved saline has become the 
reconstitution material of choice. 
The optimum concentration of BTX for injections will depend 
upon the serotype, formulation and procedure. For cosmetic use of 
Neuronox®, the volume of diluent is 2.5 ml[20].Lower concentrations are 
useful for some indications, but if adverse effects due to spread of the 
toxin to unintended targets is a problem, increasing the concentration of 
toxin and decreasing the volume injected may prevent it. On the other 
hand, data suggest that amount of injection administered does not 
contribute to diffusion; in a dose-dilution study in which a total dose of 
30 U was reconstituted in 1, 3, 5 or 10 ml, no differences in efficacy or 
safety were observed between groups[23].  
9 
Thepackage insert for Neuronox® suggests that the reconstituted 
toxin should be utilised within 4 hours, some physicians have reported 
using BTX-A 7 to 10 days after reconstitution with no observed alteration 
in potency[20], and Hexsel and colleagues found no significant differences 
in efficacy when injected within 6 weeks of reconstitution[25].The diluted 
vial is stored at 4°C . The diluted toxin is transferred to an insulin syringe 
with a 30-gauge needle is best for injecting it[26]. 
Dosing and Injection Schedules 
The therapeutic effect of BTX-A injections is usually apparent 
within a day or two and are obvious for 3 or 4 months, although they may 
last for 6 months or longer. With repeated injections, there is a tendency 
for later injections to provide aesthetic improvement that lasts longer; it is 
possible that over the course of treatment, individuals change their 
habitual use of muscles that cause expression lines. Remodelling  of the 
dermis and epidermis on a long-term basis helps to sustain the cosmetic 
effects also occurs in most individuals, because the tissue is no longer 
subjected to the same forces of muscle contraction. 
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Preoperative History and Conditions 
Hyperkinetic lines result from the repeated contraction of muscles 
perpendicular to the wrinkles. Weakening or relaxing these muscles with 
BTX-A can smooth these lines, including horizontal lines on the forehead 
(from frontalis contraction), vertical lines in the glabellar region between 
the eyebrows (caused by the corrugator muscles), horizontal creases 
across the bridge of the nose (from procerus contraction), ‘crow's feet’ 
and lateral lines along the lower eyelid (caused by contraction of the 
lateral orbicularis oculi), and perioral lines (from contraction of the 
orbicularis oris). Deep grooves or folds elsewhere that are exacerbated by 
muscle activity are also amenable to treatment. Patients 30 to 50 years of 
age may be most responsive to BTX-A, because their wrinkles are more 
likely to be caused by muscle activity than by the loss of skin elasticity 
that occurs during aging. 
CONTRAINDICATIONS  
BTX-A therapy is contraindicated in the presence of 
neuromuscular disorders that could amplify the effect of the drug, such as 
myasthenia gravis or amyotrophic lateral sclerosis. Experience with 
BTX-A in pregnant and lactating women is lacking, and it is not a 
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recommended treatment in such individuals, although inadvertent use 
during pregnancy has not resulted in any reported teratogenicity or 
pregnancy issues[27]. The possibility of drug interactions exists, and 
patients taking aminoglycoside antibiotics should be administered lower 
doses of BTX-A. As is true for most injections, BTX-A should not be 
given in the presence of active infection at that site[28-35]. 
DESCRIPTION OF TECHNIQUES  
Injections for aesthetic indications are given either intramuscularly, 
subcutaneously or intradermally . Intradermal injections are used 
especially in the Crow's feet area to minimize bruising. All of the usual 
precautions prior to any injection should be followed. The area may be 
chilled with ice before the injections to minimize any discomfort in 
sensitive individuals.  Alternatively, a topical anesthetic can be applied 15 
to 30 minutes prior to injection to minimize discomfort[35,39,45]. 
Electromyographic (EMG) guidance can be used to inject BTX 
into the most active region of the muscle. Once complete understanding 
of the relevant facial anatomy is attained, injection with an EMG system 
provides no advantage in using it. However, even experienced clinicians 
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may find EMG guidance to be useful for the occasional difficult-to-treat 
patient[39-42]. 
Glabellar Frown Lines  
Frown lines in the glabellar region are caused by contraction of the 
corrugator supercilii and orbicularis oculi muscles, which pull the brow 
medially, and the procerus muscle and depressor supercilii, which pull the 
brow inferiorly. Because the corrugator and procerus are used only to 
control facial expression, the goal of treatment should be mainly to 
produce weakening of these muscles. The treatment sites and doses 
should be individualized because the anatomical location, size and use of 
the frown muscles vary greatly between individuals. 
The patient is supine with the chin down position, insert the needle 
just above the superior bony orbital rim, directly above the inner canthus 
and inject an adequate dose–7 to 10 U in women and 15 to 20 U in 
men.The same procedure is done on the opposite side of the brow to 
ensure symmetry. Next , deliver 5 to 10 U into the procerus at the 
midline. The procedure effectively smoothes the glabellar lines at rest . 
13 
 
Crow's Feet 
Contraction of the lateral fibers of the orbicularis oculi muscle 
produces ‘crow's feet', lines that radiate from the lateral canthus. Since 
tight closure of the eyelids requires orbicularis contraction, the goal of 
treatment is to produce weakening more in the lateral orbital area, rather 
than a complete paralysis of the muscle. Because the orbicularis oculi is 
richly innervated, multiple injections are required to weaken broad areas 
of the muscle. 
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Reported total doses for the treatment of crow's feet range from 8 
to 16 U per side (in women) and 12 to 16 U per side (in men) distributed 
over multiple injection sites, with 3 to 4 U injected at a single site[27]. 
Injections are given when the patient is notsmiling, or the toxin might 
affect the ipsilateralzygomaticus complex, causing upper lip ptosis. 
Injections are placed lateral to the lateral orbital rim, because more 
medial injections can result in a side effect of temporary lower eyelid 
droop. Care is taken to avoid injecting any superficial veins.  
Horizontal Forehead Lines  
Deep horizontal creases in the forehead are caused by the repeated 
contraction of the frontalis. This vertically oriented muscle is the brow 
elevator; it inserts superiorly into the galeaaponeurotica and inferiorly 
into the skin of the brow. Unfortunately, weakening the frontalis 
sufficiently to eliminate hyperkinetic forehead lines can result in 
undesired brow ptosis with a complete lack of expressiveness. Therefore, 
the goal of treatment is to only lessen, rather than completely eliminate, 
forehead lines. Ideally, the individual will still be able to elevate the 
eyebrows, albeit to a lesser extent, after treatment . 
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of the nose. Usually one injection per side is sufficient. The area is gently 
massaged following each injection to facilitate diffusion of the toxin; 
however, too-vigorous massage or massage in a downward direction 
could also result in lip ptosis. 
Other wrinkles in face that could be treated with BTX-A include 
1) Repeated Nasal Flare - Contraction of the nasalis muscle 
accentuates the nasal flare. Injection of 5 to 10 U of BTX-A 
bilaterally into the lower nasalisfibers covering the lateral nasal 
ala- the most active area of muscle contraction produces a good 
decrease in involuntary nostril flare. 
2) Nasolabial Folds in Selected Patients 
3) Nasal Tip Droop - Contraction of the depressor septinasi, a 
muscle located at the external base of the nasal septum, pulls the 
tip of the nose downward. Injection of 2 to 3 U of BTX-A into the 
depressor septi at the base of the columella, slightly elevates the 
nasal tip. 
4) Vertical Lip Rhytides (Perioral Lines) 
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5) Upper Gum Show - The levatorlabiisuperiorisalaequenasi, muscle 
retracts the upper lip – chemo-denervation of the muscle with 
BTX-A, results in a moderate drop in the upper lip sufficient to 
cover the upper gum. 
6) Facial Asymmetry: Functional Muscle Imbalance - Injections of 
BTX-A can also be used to correct facial asymmetry resulting from 
facial nerve palsies[40], dystonias[7,41], surgery[42] or trauma[43]. 
7) Mouth Frown - The Depressor angulioris(DAO)muscle pulls 
down the corner of the mouth in opposition to the zygomaticus 
major and minor muscles. BTX-A can be used to weaken the DAO 
resulting in resetting of muscular balance, allowing the 
zygomaticus to elevate the corners of the mouth and bring them to 
a horizontal position  
8) Melomental Folds (Marionette Lines) 
9) Mental Crease 
10) Peaud'Orange (Apple Dumpling) Chin 
11) Masseteric Hypertrophy 
18 
12) Horizontal Neck Lines 
13) Platysmal Bands 
14) Adjunctive Use - BTX-A is beneficial in many patients as an 
adjunct therapy to enhance or prolong the results of other cosmetic 
procedures. To chemodenervate specific muscles prior to surgery 
to can facilitate subsequent manipulation of tissues during the 
surgery and permit a better surgical correction or a better 
concealimg of the surgical incision.  To decrease tension exerted 
on a wound or surgical incision by the underlying muscles, thereby 
promoting better healing with less scar formation. To prolong the 
effects of resurfacing[51] and many clinicians now use BTX-A 
injections along with their standard laser resurfacing protocol . 
Likewise, combination treatment with BTX-A and intense pulsed 
light (IPL) therapy may be a synergistic approach to the treatment 
of facial aging. BTX-A is also frequently used with soft tissue 
augmentation, where it prevents distortion of the filler and 
prolongs the beneficial effects of tissue augmentation . 
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POSTPROCEDURAL CARE 
Manual pressure can be applied over the injection site immediately 
after withdrawal of the needle to prevent bruising. Depending upon the 
site of injection, the physician may massage the area after the injection to 
spread the toxin, but only if it is possible to do so without spreading the 
toxin to non-targeted muscles. To minimize undesired toxin diffusion, 
patients should be directed to remain upright for at least 2 to 4 hours after 
the procedure and to refrain from rubbing or manipulating the area for 24 
hours. Because there is evidence suggesting that BTX-A binds 
preferentially at actively stimulated muscles, patients are asked to 
contract and relax the treated area as much as possible for 2 to 3 hours 
following the injections. Patients should be told to expect some transient 
redness, swelling or bruising at the injection sites, and patients should be 
advised that the effects of treatment will probably begin to diminish in 3 
or 4 months. 
COMPLICATIONS 
BTX-A occasionally affects non-targeted muscles or glandular 
tissue in the areas surrounding the injection, which can result in effects 
such as eyelid drooping , lower eyelid laxness, epiphora (excessive 
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tearing), diplopia, brow ptosis, decreased strength of eye closure, dry eye, 
mouth incompetence, difficulties in speech and the inability to whistle. 
Use of careful injection technique to target the toxin to the appropriate 
muscles and the use of concentrated low doses to limit its diffusion to 
non-targeted muscles or glands are recommended to try to prevent the 
occurrence of these adverse effects. Generally, a higher concentration 
allows for more accurate placement, greater duration of effect, and fewer 
side effects, since lower concentrations may spread the toxin widely. Of 
note, there is an area of denervation at each point of injection of size 
about 1 to 1.5 cm (diameter, 2–3 cm) that is due to toxin spread 
A quizzical or ‘cockeyed’ appearance can occur in the brow 
whenever the lateral fibers of the frontalis muscle have not been injected 
appropriately and these unparalyzed lateral fibers pull upward on the 
brow. Brow ptosis may last upto 3 months, while upper eyelid ptosis can 
persist from 2 to 12 weeks. Bruising, diplopia, ectropion, a drooping 
lower eyelid, and an asymmetric smile - caused by the spread of toxin to 
the zygomaticus major, are all reported complications of BTX-A 
injections in the periorbital area. Transient local bruising, ptosis, dry eyes, 
diplopia, and facial droop can occur with injections into the cheek. 
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Complications in the lower face involves effect on muscle function 
and facial expression, usually due to overenthusiastic use of BTX-A in 
large doses. Injections placed too close to the mouth, injection into the 
mental fold, and interaction with the orbicularis oris muscle can cause a 
flaccid cheek, incompetent mouth or asymmetric smile. Large doses 
(>100 U) of BTX-A, in the platysmaresulted in reports of dysphagia and 
weakness of the neck flexors. 
Although one of the biggest concern with the use of BTX-A is the 
formation of neutralizing antibodies leading to non-response to 
subsequent injections, the overall risk is actually low (<5%) when BTX-
A is used at usual doses for neurologic applications. Injecting the lowest 
possible effective doses, with the longest feasible intervals between 
injections, minimizes the chance for immunogenicity. Some believe that 
the total protein concentration is critical in determining potential 
immunogenicity; the protein content in currently available BTX-A is 
significantly lower than in previous batches and has been said to be less 
antigenic than the original product. Clinical experience with BTX-B is 
currently limited. However, although cross-reactive antibodies (to BTX-
A and BTX-B) do occur, cross-resistance has not been a problem. 
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There is no long-term adverse effect reported, and no systemic 
safety problems have been found with FDA-approved uses of BTX-A.  
FUTURE TRENDS 
BTX-A has become the treatment of choice for smoothing 
hyperkinetic lines in the face and neck, creating a more pleasant and 
youthful appearance. Alone or in combination with surgery, soft-tissue 
augmentation, or ablative and non-ablative laser resurfacing, BTX-A 
treatment is both an art and a science, with its use in facial sculpting and 
enhancing, along with dermatologic correction. Moreover, the number of 
dermatologic indications for BTX-A is likely to continue to grow. Easy to 
use, minimally invasive, very well tolerated by patients and extremely 
safe, injections of BTX-A can be used alone or in combination with other 
cosmetic procedures and are an integral part of most cosmetic practices. 
sHYPERHIDROSIS 
Sweating is an essential thermoregulatory function. When the 
internal temperature rises, there are two main mechanisms to cool the 
body: radiative cooling due to cutaneous vasodilation and evaporative 
cooling due to sweat. Most sweat is produced by the eccrine sweat 
glands, and heat is dissipated as energy released by evaporation from the 
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skin surface. The designation ‘sweat’ has been applied to both the eccrine 
and apocrine glands, as well as to their secretory products, i.e. eccrine 
sweat and apocrine sweat . For the purposes of this discussion, the term 
‘sweat’ applies to eccrine glands and their secretory products unless 
otherwise specified. 
There are 2-5 million eccrine glands distributed within the skin of 
each individual. Only on the clitoris, glans penis, labia minora, external 
auditory canal and lips are they absent. The ductal orifices of the eccrine 
glands are visible only on the palms and soles, where, with 20- to 30-fold 
magnification, they can be seen along the dermatoglyphic ridges. 
In healthy individuals, eccrine sweat is 99% water. The average 
adult can produce over 0.5 liters of sweat per hour, and trained athletes or 
those acclimatized to hot environments can produce up to 3-4 liters per 
hour[62]. Physically fit or acclimatized persons also initiate sweating 
earlier and conserve sodium, chloride and other electrolytes more 
efficiently than unconditioned individuals, resulting in cooling with 
minimal effect on water and electrolyte balance. Precision of 
thermoregulatory control is similar in men and women and diminishes 
only slightly with age[63]. 
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Sweating is a reflex function that is primarily controlled through 
the sympathetic nervous system. These nerves are anatomically 
sympathetic but functionally cholinergic (i.e. acetylcholine, rather than 
norepinephrine, is the principal terminal neurotransmitter). Neural 
impulses for sweating (sudomotor impulses) travel from the anterior 
hypothalamus through the reticulospinal tracts to the appropriate level in 
the spinal cord, out through the rami communicantes to autonomic 
ganglia and then within sympathetic cholinergic neurons to the secretory 
cells of the eccrine glands. Adrenergic innervation has also been 
demonstrated for the eccrineglands, but it is not believed to be 
physiologically important[64]. In addition, the sweat glands, via a direct 
effect on the secretory cells, respond to certain drugs (e.g. cholinergic 
agonists) as well as to the local application of heat. 
HYPERHIDROSIS 
Hyperhidrosis is excessive production  of sweat. The most widely 
used classification system divides it into primary and secondary types. 
Other classification systems separate hyperhidrosis into categories based 
on the source of the neural impulses that drive it: cortical (emotional), 
hypothalamic (thermoregulatory), medullary (gustatory), spinal cord and 
local axon reflexes. 
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Primary hyperhidrosis, the most common type, is characterized by 
excessive sweating localized to the palms, soles and/or axillae. It is 
stimulated by intense emotion or stress, and, in general, patients only 
have excessive sweating during waking hours. Primary hyperhidrosis is 
thought to arise from increased neural impulses from the cerebral cortex 
to the eccrine gland (hence the term ‘cortical’ hyperhidrosis). The glands 
themselves are normal in structure.  
Secondary hyperhidrosis may be localized or generalized and is 
associated with medical conditions such as genetic syndromes, 
malignancy or infection. 
Primary hyperhidrosis 
Primary hyperhidrosis is defined as excessive sweating in localized 
areas (usually the palms, soles and/or axillae) that is not associated with a 
systemic disorder. Table 2.1 lists the diagnostic criteria[66]. Men and 
women of all races are equally affected. A family history can be elicited 
in 60-80% of patients with primary hyperhidrosis[67], with a pattern of 
inheritance suggesting autosomal dominant transmission with incomplete 
penetrance. Recently, a locus for primary palmar hyperhidrosis was 
mapped to chromosome 14q in three Japanese families[68]. 
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Table 2.1 
Criteria for the diagnosis of primary hyperhidrosis 
CRITERIA FOR  PRIMARY HYPERHIDROSIS 
 
1. Focal, visible excess sweating 
 
2. Present for at least 6 months 
 
3. No apparent secondary causes 
 
4. At least 2 of the following:  
 
• Bilateral and symmetric 
 
• Impairs activities of daily life 
 
• At least 1 episode per week 
 
• Age of onset <25 years 
 
• Positive family history 
 
• Stops during sleep 
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Intense emotion or stress can elicit sweating in anyone. It occurs 
most often on the palms, soles or axillae and can also affect the face, 
especially the forehead and the cutaneous upper lip. The post-orgasmic 
sweating observed with sexual activity[69] may also derive from emotional 
stimulation. 
Clinically significant primary hyperhidrosis occurs in two major 
forms, volar (palmoplantar) and axillary, which can coexist[62]. One of the 
two forms usually predominates as a problem in a given individual. The 
onset of volar hyperhidrosis is often during childhood, whereas axillary 
hyperhidrosis typically develops at or soon after puberty. Primary 
hyperhidrosis is seen in both cold and warm environments, but it is 
usually more problematic in hot weather. A chronic and unremitting 
course is characteristic, with little or no variation in association with age, 
disease or hormonal status. 
Volar hyperhidrosis is the most common form of primary 
hyperhidrosis , affecting approximately 50-60% of patients[64,65]. The 
entire palm and sole, as well as the lateral aspects, tips and distal dorsal 
skin of the fingers, display sweating. Affected individuals are severely 
compromised socially and at work or school, with contamination of paper 
or work materials and embarrassment when shaking hands. As it begins 
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during childhood, it can cause self-conscious withdrawal from various 
social activities and sports. 
Axillary hyperhidrosis is the second most common form of primary 
hyperhidrosis, affecting 30-50% of patients[65]. Affected individuals 
experience wet, stained clothing and unpleasant sweat trickling down the 
trunk. The right axilla usually produces more sweat than the left (60-40). 
Exceptionally, one axilla may be hyperhidrotic while the opposite axilla 
is hypohidrotic or virtually anhydrotic. These patients find work or social 
activities difficult to impossible. Odor (axillary bromhidrosis) is usually 
absent; the excessive quantities of eccrine sweat presumably wash away 
or dilute odorogenic apocrine sweat droplets and bacteria. 
Secondary Hyperhidrosis  
Secondary hyperhidrosis is caused and or associated with another 
systemic disorder. It can be localized to palmoplantar, axillary or other 
cutaneous sites or it may be generalized. There are many causes, which 
can be divided into categories based on the source of the neural impulse 
driving the response: cortical, hypothalamic, medullary, spinal or local. 
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Causes of cortical hyperhidrosis 
  CAUSES OF CORTICAL HYPERHIDROSIS 
Primary hyperhidrosis 
Secondary hyperhidrosis 
Disorders of cornification 
 
• Palmoplantarkeratodermas 
 
• Pachyonychiacongenita 
 
• Congenital ichthyosiformerythroderma (bullous and non-
bullous forms) 
 
Other genodermatoses 
 
• Epidermolysisbullosa: simplex >junctional 
 
• Dermatopathiapigmentosareticularis 
 
• Dyskeratosiscongenita 
 
• Pachydermoperiostosis (digital clubbing and thick, furrowed 
skin on the face and scalp) 
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  CAUSES OF CORTICAL HYPERHIDROSIS 
 
• Apert syndrome (craniosynostosis, digital anomalies, severe 
acne; FGFR2 mutations) 
 
• Nail–patella syndrome 
 
Hereditary sensory and autonomic neuropathies (HSANs)[‡] 
 
• Familial dysautonomia (Riley–Day syndrome; HSAN type III)
 
• Congenital autonomic dysfunction with universal pain loss 
 
• Congenital sensory neuropathy (HSAN type II) 
 
 
 
  
31 
Table 2.2 
Drugs that can stimulate eccrine sweating 
DRUGS THAT CAN STIMULATE ECCRINE SWEATING 
Direct-acting cholinomimetic agents 
• Acetylcholine 
 
• Anti-xerostomia drugs  
– Cevimeline 
– Pilocarpine 
 
• Methacholine 
 
Cholinesterase inhibitors 
 
• Anti-Alzheimer's drugs  
– Donepezil 
– Galantamine 
– Rivastigmine 
– Tacrine 
 
 
• Anticholinergic antidote  
– Physostigmine 
 
 
• Antimyasthenics 
– Ambenonium 
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DRUGS THAT CAN STIMULATE ECCRINE SWEATING 
– Edrophonium (for diagnosis) 
– Neostigmine 
– Pyridostigmine 
 
 
 
Adrenomimetic agents 
• Dopamine 
• Epinephrine 
• Isoproterenol 
• Norepinephrine 
• Phenylpropanolamine 
 
Antidiabetic (hypoglycemic) agents 
• Insulins 
• Sulfonylureas 
 
CNS stimulants 
• Amphetamines 
• Caffeine 
• Theophylline 
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Antidepressants 
 
• MAOIs 
– Isocarboxazid 
– Phenelzine 
– Selegiline 
– Tranylcypromine 
 
• SSRIs  
– Duloxetine 
– Fluoxetine 
– Paroxetine 
– Sertraline 
 
• Tricyclics 
– Amitriptyline 
– Amoxapine 
– Desipramine 
– Doxepin 
– Imipramine 
– Maprotiline 
– Nortriptyline 
34 
– Protriptyline 
– Trimipramine 
 
• Other  
– Buspirone 
– Trazodone 
 
Antipsychotics 
 
• Phenothiazines 
– Chlorpromazine 
– Fluphenazine 
– Perphenazine 
– Thioridazine 
– Triflupromazine 
 
• Other typical antipsychotics  
– Chlorprothixene 
– Haloperidol 
– Loxapine 
– Molindone 
– Thiothixene 
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Antipyretics 
• Acetylsalicylic acid 
• NSAIDs 
 
Opioids 
• Fentanyl  
• Meperidine 
• Methadone  
 
Other drugs 
• Atomoxetine 
• Dextromethorphan  
• Ipecac 
• Pentoxifylline 
• Sibutramine 
• Sumatriptan 
• Tramadol  
• Yohimbine 
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Localized sweating can be observed in certain inflammatory skin 
disorders and at times in the skin immediately surrounding an intradermal 
injection site. Direct stimulation of a cutaneous sympathetic axon can 
induce sweating in an area approximately 4 cm in diameter[64]. The 
response is minimal and rarely noticed. Electrical and physical impulses 
as well as subcutaneous injection of drugs with nicotine-like effects on 
autonomic ganglia can incite this local form of hyperhidrosis. 
Presumably, mediators from inflammatory skin conditions (e.g. psoriasis, 
dermatitis) can also elicit localized hyperhidrosis. Substance P is believed 
to participate in the mediation of axon reflex sweating, and a number of 
other mediators, including kinins, dopamine, prostaglandins, angiotensin 
and adenine, may be involved[78]. 
Diagnosis of Hyperhidrosis  
Key features 
 
▪ Differentiation between primary and secondary hyperhidrosis is 
important 
 
▪ Colorimetric and gravimetric methods document hyperhidrosis 
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The first step in the diagnosis of excessive sweating is to 
differentiate between primary and secondary hyperhidrosis. History will 
elicit location, duration and specific triggers. Other medical disorders and 
medications (including over-the-counter products) must be documented. 
An extensive review of systems should point to any secondary causes. 
Patients with primary hyperhidrosis report excessive sweating of 
the volar and/or axillary areas triggered by stress, typically with an onset 
during childhood or adolescence. They usually have a positive family 
history and the review of systems is negative for secondary causes. 
Examination shows shiny, wet palms and soles or excessive sweat stains 
on clothing. These findings are sufficient to make the diagnosis . 
Patients who do not fit the classic pattern of primary hyperhidrosis 
should undergo further evaluation with a directed history focused on 
possible etiologies  and a complete physical examination. Laboratory 
testing and radiographic studies may be needed . 
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Table 2.3 
Initial patient evaluation for secondary hyperhidrosis 
INITIAL PATIENT EVALUATION FOR SECONDARY 
HYPERHIDROSIS 
Laboratory test Disease 
Serum electrolytes, BUN, 
creatinine 
Renal disease (rare) 
Blood glucose level Diabetes mellitus 
Thyroid function tests Hyperthyroidism 
Skin test for tuberculosis (e.g. 
PPD) 
Tuberculosis 
Chest X-ray Tuberculosis, neoplasm 
Complete blood count Infection 
Sedimentation rate Infection, neoplasm, inflammatory 
disease 
Antinuclear antibodies Autoimmune connective tissue disease
Urinary catecholamines[*] Pheochromocytoma 
Further evaluation depends upon results . 
* If suggestive signs or symptoms. 
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Measurement of sweat can be performed when such documentation 
is required. A grading scale for volar disease lists ‘low’ as a moist palm 
or sole without visible sweat droplets. ‘Moderate’ disease is characterized 
by sweating toward the finger tips. ‘Severe’ cases drip sweat. Axillary 
involvement can be measured by the sweat stains on clothing. A stain of 
<5 cm is considered normal; 5-10 cm, mild; 10-20 cm, moderate; and >20 
cm, severe. 
Colorimetric techniques such as the starch–iodine or 
quinizarinmethods[79] demonstrate the sweating pattern and will also 
reveal the location of the most active sweat glands in a given area. In the 
starch– iodine technique, iodine solution (e.g. 3.5% in alcohol) is applied 
to clean, shaved skin and allowed to dry, then starch powder (e.g. 
cornstarch) is brushed onto the area; the mixture turns blue–black in sites 
with sweating . A combination of paper impregnated with starch and 
iodine can also be utilized . Although not routinely performed in patients 
with hyperhidrosis, these tests can be used to plan treatment with 
botulinum toxin or local surgical ablation. 
Additional quantitative assessment methods are available. In order 
to document amounts of sweat produced, gravimetric (via weighing filter 
paper before and after application to the skin) and evaporative (via a 
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device that assesses water vapor loss from the skin) measurements can be 
made in volar or axillary sites[79]. Most patients with axillary 
hyperhidrosis will produce at least 100-300 mg of sweat in a 5-minute 
test period with mental arithmetic as a sweating stimulus. Infrared 
thermography represents another method of evaluating sweat gland 
function, allowing comparison between anatomic areas and even 
individual glands. 
Treatment of Hyperhidrosis  
Key features 
 
▪ Treatment options for hyperhidrosis include topical preparations, 
iontophoresis, oral anticholinergics or α-adrenergic blockers, 
biofeedback therapy, botulinum toxin and surgical procedures 
 
 
 Although over-the-counter antiperspirants are usually not strong 
enough to significantly improve the problem, more effective topical 
preparations are available; 20% aluminum chloride hexahydrate or 6.25% 
aluminum tetrachloride is usually the first-line treatment for localized 
hyperhidrosis. These solutions should be applied to dry surfaces at night, 
when sweating is diminished. Occlusion with gloves or plastic film 
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enhances penetration of the drug. Application is recommended for three 
to five consecutive nights, then one to two times a week as needed to 
control sweating. Treated skin can be washed the following morning. The 
salt precipitates in the sweat duct and blocks it. With chronic use, atrophy 
of secretory cells may be induced, and in some instances the entire 
eccrine unit degenerates. Burning and irritant contact dermatitis are 
common side effects, particularly in women who shave their axillae[23].  
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Table 2.4 
Treatment of hyperhidrosis 
TREATMENT OF HYPERHIDROSIS 
 Therapy Frequency Side effects Duration Comments 
First-
line 
Topicals 20% 
aluminum 
chloride 
hexahydrate 
6.25% aluminum 
tetrachloride 
Zirconium salts 
Aldehydes 
Use 
nightly for 
3–5 nights, 
then every 
few days 
as needed 
Burning 
Irritant contact 
dermatitis 
Days Blocks sweat 
ducts 
Aldehydes not 
recommended 
due to 
sensitization 
Second-
line 
Iontophoresis 2–3 times a 
week 
Discomfort 
during 
procedure 
Days Blocks sweat 
ducts 
Botulinum toxin 
A 
Every 4–6 
months 
Discomfort 
during 
injection 
Weakness of 
underlying 
muscles 
Months Prevents release 
of acetylcholine
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TREATMENT OF HYPERHIDROSIS 
 Therapy Frequency Side effects Duration Comments 
Oral therapy As needed  Hours  
Oxybutynin 
Glycopyrrolate 
1.25–5 mg 
bid 1–2 mg 
bid 
Dry mouth and 
urinary 
retention most 
common; also 
confusion and 
decreased 
mental status 
 Anticholinergic 
Anticholinergic
Clonidine 0.1–0.3 mg 
bid 
Hypotension, 
rebound 
hypertension 
 α2-Adrenergic 
agonist 
Clonazepam 0.25–0.5 
mg bid 
Sedation  Anxiolytic 
Third-
line 
Local excision Once Scarring Permanent Last resort 
Sympathectomy  Compensatory 
hyperhidrosis 
Horner's 
syndrome 
Usually 
permanent 
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Some patients who sweat significantly at night require a 
preliminary dose of an anticholinergic (glycopyrrolate 1 mg or 
propantheline bromide 15 mg) 1 hour before application for the first few 
applications. This reduces sweating enough to prevent washing away of 
the topical solution. Other topical preparations include zirconium salts, 
which may be effective in the axillae but are generally not helpful on 
volar skin. Topical aldehyde agents such as formaldehyde and 
glutaraldehyde are effective, especially for volar disease. However, they 
have been abandoned due to frequent allergic sensitization that can result 
in cross-reactions with aldehydes in the environment (e.g. in lotions, 
soaps, shoes). Other side effects include discoloration of the skin. 
Tap water iontophoresis over 20 minutes two to three times a week 
may be helpful. The mechanism of action is unknown but is believed to 
relate to blockage of the eccrine duct within acrosyringium. Side effects 
are minimal and include tingling of the skin during treatment. 
Introduction of anticholinergic medications via iontophoresis is not 
advised, owing to systemic absorption and unacceptable side effects. 
Oral anticholinergics will decrease sweating in most patients. The 
most commonly used agents are oxybutynin[80] and glycopyrrolate[81]. 
Unfortunately, high doses are often required to control the hyperhidrosis 
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and unacceptable side effects frequently occur at these doses, including 
dry eyes, dry mouth, insomnia, mental status changes (e.g. confusion, 
hallucinations), palpitations, seizures, blurred vision, bowel disturbances, 
urinary retention and hypertension. 
Clonidine (an α2-adrenergic agonist that decreases central 
sympathetic outflow) and phenoxybenzamine (an α-adrenergic blocker) 
have been used with some success in anecdotal reports[82,83]. Potential 
side effects include hypotension, rebound hypertension, sedation, 
constipation, weakness and headache. 
Botulinum toxin type A (BTX-A) has been approved by the Food 
and Drug Administration in the US for the treatment of axillary 
hyperhidrosis; it is also effective for volar disease. BTX-A works by 
preventing release of acetylcholine from cholinergic neurons . Injection 
into hyperhidrotic skin will produce near anhidrosis for 4 to 6 months. 
Side effects, if any, are short-lived. Pain during injection is the most 
common complaint–when given in volar sites, a regional nerve block is 
usually performed prior to the procedure. Topical anesthetics are typically 
sufficient for the axilla. Muscle weakness, especially of the intrinsic 
muscles of the hands or feet, may occur and resolves spontaneously over 
2 to 5 weeks. Compensatory hyperhidrosis has not been observed[84]. 
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Surgical treatment represents the final option after other 
therapeutic modalities have failed. Excision of the sweat glands is often 
effective for axillary disease, but radical resection of the entire axillary 
skin causes significant scarring. Compensatory hyperhidrosis is not seen 
with this form of local surgery. Newer methods include removal or 
destruction of the axillary sweat gland layer by surgical dissection, 
curettage or liposuction[84,]. 
Although sympathectomy is the last resort for patients with volar 
hyperhidrosis, advances in endoscopic surgery have decreased the 
morbidity associated with this procedure. Sympathectomy at the T2–T3 
level for palmar disease and the lumbar area for plantar disease is 
effective. Risks of the procedure include Horner's syndrome, hypotension 
and pneumothorax. Compensatory hyperhidrosis of the trunk or gustatory 
facial sweating may occur[23] and the hyperhidrosis may gradually recur. 
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MATERIALS AND METHODS 
STUDY DESIGN 
Type of study: Prospective non-randomized interventional study. 
Place of study: Department of Dermatology, 
Government Stanley Medical College, Chennai 
Study period : May 2011 to October 2012 ( 18 months) 
   First 6 months: Interventional period 
   Next 12 months: Follow-up period 
Sample size:  30patients of both sexes; age group: 15 to 75 years 
    20 patients with palmoplantar hyperhidrosis 
   10 patients with horizontal frontal line or crow’s feet. 
The patients enrolled for the study were pooled from those 
attending the Dermatology out patient department. Initially , 30 patients 
with palmoplantar hyperhidrosis who came with complaints of excessive 
sweating of  palms and soles ; 20 patients with facial wrinkles were 
subjected to the pre-procedure consultation, assessment and 
investigations as given below. Out of them , 20 patients with 
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palmoplantar hyperhidrosis, 7 patients with Crow’s feet , 3 patients with 
horizontal frontal lines were enrolled according to the inclusion and 
exclusion criteria. The mean age group was     years of both sexes. 
PRE- PROCEDURE CONSULTATION  
¾ Thorough explanation of the procedure , course of treatment and 
potential adverse effects were explained 
¾ Informed and written consent were obtained 
¾ A thorough history regarding the onset , duration, etiological 
factors, complications, other systemic illness , hypersensitivity to 
any drugs, pregnancy, lactation and past history regarding any 
modes of treatment for the condition  was taken. (ANNEXURE-I) 
PRE- PROCEDURE ASSESSMENT 
A meticulous examination as given in ANNEXURE –I was done 
with the following assessments 
- Minors starch iodine test 
- Hyperhidrosis severity scoring  scale 
- Photographic recording 
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Investigations  
In all the patients bleeding time and clotting time was measured. 
With the history. Clinical examination and the aid of laboratory 
investigations, patients were selected according to the inclusion and 
exclusion criteria. 
Inclusion criteria  
1) Age 15 – 70 years. 
2) Sex – both  Male  & Female 
3) Willing to be enrolled for the complete study period 
4)  Patients not responding to medical management   
Exclusion criteria  
1) Patient with neuromuscular disorders. 
2) Pregnancy  
3) Lactation. 
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4) Patients receiving drugs  with neuromuscular blocking   
properties like amino glycosides, spectinomycin in the previous 
3 days. 
5) Patients with known hypersensitivity to BTX-A. 
Procedure  
Requirements  
¾ Botulinum toxin A vial – 100 units (NEURONOX) 
¾ 0.9% saline as diluent 
¾ Insulin syringes 
¾ Gloves  
¾ Alcohol swabs 
¾ Sterile gauze 
¾ Ice packs 
¾ Topical anaesthetic (EMLA) 
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Technique 
Preparation of injection  
The BTX-A containing vial is diluted with 2.5ml of normal saline 
and gently rolled between fingers to get a clear solution. The diluted 
solution is withdrawn into insulin syringes the volume in each according 
to convenience. The dosage calculation  is 1 unit marking in syringe 
corresponds to 1 unit of BTX-A. 
Positioning of patient  
Patient is in recumbent position for comfort and convenience.  
Preparing the patient 
Intradermal test for BTX-A is given over volar aspect  of left 
forearm. 
Anaesthesia – topical anaesthetic (EMLA) is applied over the 
injection sites under occlusion until adequate anaesthesia is achieved. 
The skin where the injection is to be given is wiped with surgical 
spirit. 
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Hyperhidrosis – the dominant hand of the patient is chosen for 
injection with the other kept as control. 
Facial wrinkles – both sides are treated with injection sites marked 
with skin marking pencil. 
Injection of BTX-A 
Hyperhidrosis – the palm is divided into squares of area 2 cm2 and 
2 units of  BTX-A is injected intradermally into the centre of each square. 
In the palmar aspect of fingers 2 units is injected into the centre of each 
phalanx. 
Wrinkles – 
Forehead lines – two rows of equally spaced points which are 2 cm 
apart are marked on the forehead as shown in the pictures. The lower row 
should be at least 1 cm above the brow and the inter-row distance should 
be 2 cm. 
Crow’s feet – 3 injection sites on each side are marked ; the first 
1cm away from the bony margin from lateral canthi ; two other points 1 
cm above and below the first point and just medial to it are marked a as 
shown in the pictures. 
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Immediately after the procedure ice packs are placed over the 
injection sites for 3 – 5 minutes. 
Post procedure advice  
To avoid lying down for 4 hours in patients treated for wrinkles. 
To avoid any rigorous activity of the injected hand . 
Follow up  
Hyperhidrosis: 1st day, 10th day, 4th week, 8th week, 16th  week and 
24th  week and once in 3 months after that. 
At each visit minors starch iodine test and severity assessment 
using scoring system were done. 
Wrinkles: 1st day, 10th day, every 4 weeks thereafter 
At each visit photographic assessment was done. 
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HYPERHIDROSIS DISEASE SEVERITY 
SCORE 
1 
Sweating is not noticeable and never interfere 
with daily activities 
2 
Sweating is tolerable but sometimes interferes 
with daily activities. 
3 
Sweating is barely tolerable and frequently 
interferes with daily activities. 
4 
Sweating is intolerable and always interfers with 
daily activities 
 
Response rate  
 In both hyperhidrosis and wrinkles maximal response to treatment 
is recorded on the 10th day after treatment and the response were assessed 
using the following criteria 
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Hyperhidrosis 
Complete response – more than 75% reduction in sweating with severity 
score of l. 
Partial response – between 35% to 75% reduction in sweating with 
severity score of 2. 
No response – less than 35% reduction in sweating with severity score of 
3 and above. 
Wrinkles 
Complete response – more than 75% reduction in visible wrinkles. 
Partial response  – between 35% to 75% reduction in visible wrinkles. 
No response –no significant reduction in visible wrinkles. 
RELAPSE RATE 
In both the conditions relapse was taken as complete recurrence of 
symptoms similar to that before treatment. 
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RESULTS 
Total no. of patients in the study : 30 
The sex distribution of the patients included in the study 
Male 7 
Female 21 
 
The age wise distribution of  patients 
15 – 35 20 
36 – 55 8 
56- 75 2 
  
The average age of the patients in the study group : 35.5  
  
57 
 
 
 
 
THE RESPONSE RATE  
 HYPERHIDROSIS WRINKLES 
Complete response 18/20(90%) 7/10(70%) 
Partial response 2/20(10%) 3/10(30%) 
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THE RECURRENCE RATE  
 4th week 8th week 16th week 24th week 
Relapse rate 
for 
hyperhidrosis 
2/20(10%) 3/20(15%) 5/20(25%) 16/20(80%) 
Relapse rate 
for wrinkles 
1/10(10%) 2/10(20%) 4/10(40%) 6/10(60%) 
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Interpretation of results  
¾ BTX-A is in effective in both hyperhidrosis and wrinkles with most 
patients having complete response. 
¾ The duration of the response  maintained  has inter-patient variability 
with an average of  14 weeks. 
COMPLICATIONS OBSERVED 
¾ The following complications were noted in the study 
COMPLICATIONS NO.OF PATIENTS 
Pain over the treated site 3 
Hematoma over the site 2 
Hand muscle weakness  3 
 
¾ No immediate complications like hypersensitivity , were noted. 
¾ No serious complication like ptosis were noted. 
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DISCUSSION 
Hyperhidrosis 
Several medical managements are available for focal hyperhidrosis 
in the form of Topical antiperspirants like 1% formalin and aluminium 
chloride solutions. The disadvantage with these agents are that their mean 
duration of action is roughly few hours  so they have to be applied on a 
daily basis resulting in poor patient compliance. 
Oral agents like anticholinergic, beta blockers are sought with 
significant systemic side effects. 
Iontophoresis requires minimum of thrice weekly to daily sittings 
depending upon the response which roughly lasts from few hours to few 
days. Few patients might be resistant to all the above modalities of 
treatment. 
Botulinum toxin 
In anearlier study done by Solomon and Hayman, 20 subjects 
having recalcitrant palmar and digital hyperhidrosis were treated with 
botulinum toxin type A , 50 - 65 U in one hand. Treatment reduced sweat 
production significantly in the treated areas, with effect lasting from 4 to 
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9 months, although reduced sweating persisted in all patients for the 12-
month evaluation period. 
Another study by Bodokh and Branger compared the effectiveness 
of BTX-A given in one hand compared with no treatment in the other 
control hand. Assessments included subjective and objective 
measurements, using gravimetric scales and Minor's iodine starch test. 
This study showed a significant improvement in 15/20 (75%) patients 
treated for palmar hyperhidrosis, with no serious adverse events . 
(Evidence levels: IIa, III) 
It has been expressed that botulinum toxin type A injections in the 
palm may impede the release of acetylcholine at the neuromuscular 
junctions, thereby decreasing muscle tone and function in the hand; 
however, this has not been found to be true (Evidence level: IIb). Lowe et 
al. investigated the effectiveness of BTX-A vs. placebo in the treatment 
of palmar hyperhidrosis in 19 patients and concluded that patients 
experienced a significant improvement in palmar hyperhidrosis without a 
concomitant decrease in grip strength, finger dexterity, or the occurrence 
of any adverse events (Evidence level: Ib).  
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Our study results correlated well with the above studies in that all 
patients treated had good response which lasted for an average of 14 
weeks with no serious adverse events though transient hand weakness 
were noted in 50% of those treated. 
Pain during injection can be addressed through application of ice 
packs, use of the Dermojet delivery system or anesthetic procedures 
Wrinkles 
The cosmetic awareness in our society has recently witnessed a sea 
change with more number of people, both men and women giving 
significant importance to aesthetics in day to day life. The appearance of 
the skin in particular that of the face in terms of colour, texture and 
smoothness has gained undue social significance and the dissatisfaction 
with it can result in significant social morbidity, withdrawal, low self-
esteem and so on. People are willing to undergo aesthetic procedures 
despite the cost. In this background botulinum toxin has gained 
importance both as a monotherapy and as an adjunct to several other 
aesthetic procedures. In the treatment of facial wrinkles, botulinum toxin 
A has been found to effective and has received FDA approval for the 
treatment of upper face. The dermatologist of this era is bound to have 
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adequate knowledge, experience and expertise of this unique treatment 
modality. 
Many studies done by Blitzer et al and Pribitkin et al have shown 
the effectiveness of botulinum injections for hyper functional lines.These 
studies confer certain characteristics of successfully treated patients. The 
ideal patients are the ones with thin skin, fine wrinkles, lines that are 
exacerbated by muscle contraction, and hyperfunctional lines that can be 
spread out with their fingers. Blitzer et al described a "glabellar-spread 
test" in which the physician is able to spread out the 
hyperfunctionalglabellar lines to project the maximum benefit that a 
paralytic injection could achieve. 
Carruthers et al, in a consensus panel article, stated that panel 
members agreed that preserved saline could also be used.An insulin 
syringe with a 30-gauge needle works nicely for injection. The insulin  
syringe does not waste any of the solution in the hub of the syringe. Some 
clinicians are moving to 32-gauge needles, which has better patient 
tolerance. 
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Indication/Scenario for Reinjection 
If a patient feels dissatisfied with the original injection, reinjection 
can be performed 1 week post-injection. However, 2-3 weeks after the 
first injection is probably a more practical time for a return clinic visit. 
Normally , 2.5-5 U are used for reinjection. Reinjection strategies are yet 
to evolve. If the patient has a satisfactory result with reinjection, the next 
visit is at 2-3 months or when the patient requests another treatment. 
Complications 
The most dreaded complication is temporary paralysis of nearby 
facial musculature. Nearly 1-3% of patients may experience a temporary 
upper lid or brow ptosis; the most serious complication to the patient is 
upper lid ptosis. This results when there is migration of the botulinum 
toxin to the levatorpalpebraesuperiorismuscle. The ptosis usually persist 
for 2-6 weeks. It can be treated with topicalapraclonidine. This is an 
alpha-adrenergic agent that stimulates the Müller muscle and immediately 
elevates the upper eyelid. This treatment can usually raise the eyelid 1-3 
mm. Treatment with1-2 drops 3 times per day continues until the ptosis 
resolves. 
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Bruising usually occurs if a small vein is lacerated or a patient is on 
aspirin, vitamin E, or NSAIDs. Strictly , patients should stop taking these 
products 2 weeks before the procedure. Headaches can occur after 
injections; however, in one study done by Carruthers et al, this did not 
exceed the placebo group.6This is due to the trauma of the injection and 
not something inherent in the toxin. In fact, botulinum toxin injections are 
quite safe. To date, no significant long-term complication ofbotulinum 
toxin injections has been identified 
Future 
The popularity of BTX is incredible in the field of cosmetic 
surgery. The use and scope of botulinum toxin increases every year. 
Patients have shown a very high degree of satisfaction with this 
procedure. Current research focuses on using BTX as an adjunct therapy 
to a myriad of surgical and ablative procedures. 
Botulinum toxin A has been used in significant numbers for the 
past 20 years. It has proved to be an extremely safe strategy for 
selectively inducing muscle paralysis. 
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CONCLUSION 
The following are the conclusions derived from this study 
¾ Botox is a valuable treatment for both hyperhidrosis and facial 
wrinkles. 
¾ Botox is effective in a single sitting.  No other treatment modality 
for hyperhidrosis is effective in a single sitting. 
¾ The results of this study show that complete response to botox was 
seen in 18/20(90%) and partial response in 2/20(10%) patients 
treated for hyperhidrosis. 
¾ Complete response was seen in 7/10(70%) and partial response in 
3/10(30%) in those treated for wrinkles. 
¾ The recurrence rate was 16/20(80%) and 6/10(60%) in 
hyperhidrosis and wrinkles respectively at the end of 24 weeks. 
¾ Only minor side effects like pain after injection, hematoma, and 
mild hand muscle weakness were noted.  
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¾ No major complications like anaphylaxis, ptosis, paralysis of facial 
or hand muscles were observed.  
¾ The cost involved may be a factor and therefore this treatment 
should offered to patients with hyperhidrosis when 
Not responding to other modalities of treatment. 
A quick response is needed ahead of socially important situations 
like an examination, marriages etc. 
¾ Hence BTX is a safe, in-office procedure which can be performed 
without hospitalisation when done by a well-trained dermatologist 
with expertise. 
BIBILIOGRAPHY 
1) Frank J. Erbguth (2004). "Historical notes on botulism, Clostridium 
botulinum, botulinum toxin, and the idea of the therapeutic use of 
the toxin". Movement Disorders (John Wiley & Sons, on behalf of 
the Movement Disorder Society) 19 (S8): S2–S6. 
doi:12.1002/mds.20003. PMID15027048. 
2) vanErmengem, E.P. (February 1898). "Uebereinenneuenanaëroben 
Bacillus und seine BeziehungenzumBotulismus" (in German). 
Zeitschriftfür Hygiene und Infektionskrankheiten26 (1): 1–56. 
doi:10.1007/BF02220526. PMID399378. 
3) Snipe, P. Tessmer&Sommer, H. (August 1928). "Studies on 
Botulinus Toxin, 3. Acid Precipitation of Botulinus Toxin". The 
Journal of Infectious Diseases, (University of Chicago Press) 43 
(2): 152–160. doi:10.1093/infdis/43.2.152. ISSN0022-1899. 
JSTOR30083772. 
4) A. S. V. Burgen, F. Dickens, and L. J. Zatman (August 1949). "The 
action of botulinum toxin, on the neuro-muscular junction". The 
Journal of Physiology (University of Chicago Press) 109 (1–2): 
10–24. PMC1392572. PMID15394302. http://www.jphysiol.org/ 
cgi/pmidlookup?view=long&pmid=15394302. 
5) In: Jankovic J, Hallett M, ed,Therapy with Botulinum Toxin, New 
York: Marcel Dekker; 1994. 
6) Eleopra R, Tugnoli V, Rossetto O, et al: Different time courses of 
recovery, after poisoning with botulinum neurotoxin serotypes A 
and E in humans. NeurosciLett 1998; 256:135-138.  
7)  Scott AB: Botulinum toxin injection, into extraocular muscles as 
an alternative to strabismus surgery,Ophthalmology 1980; 
87:1044-1049.  
8) Carruthers J, Stubbs HA: Botulinum toxin for benign essential 
blepharospasm, hemifacial spasm and age-related lower eyelid 
ectropion,Can J NeurolSci 1987; 14:42-45.  
9) Jankovic J, Schwartz K: Botulinum toxin injections, for cervical 
dystonia. Neurology 1990; 40:277-280. 
10) Glogau R: Botulinum A neurotoxin for axillary hyperhidrosis ,No 
sweat Botox. DermatolSurg 1998; 24:817-819.  
11) Silberstein S, Mathew N, Saper J, et al: Botulinum toxin type A,  a 
migraine preventive treatment. Headache 2000; 40:445-450.  
12) Blumenfeld A: Botulinum toxin type A, an effective prophylactic 
treatment in primary headache disorders. Headache 2003; 43:853-
860.  
13) Porta M: A comparative trial of botulinum toxin type A , 
methylprednisolone for the treatment of myofascial pain syndrome 
and pain from chronic muscle spasm. Pain 2000; 85:101-105. 
14) Ranoux D, Gury C, Fondarai J, Mas JL, Zuber M: Respective 
potencies of Botox and Dysport: a double blind, randomised, 
crossover study in cervical dystonia.,JNeurolNeurosurg Psychiatry 
2002; 72:459-462.  
15) Simonetta Moreau M, Cauhepe C, Magues JP, Senard JM: A 
double-blind, randomized, comparative study of DysportvsBotoxin 
primary palmar hyperhidrosis,Br J Dermatol 2003; 149:1041-1045.  
16) Ramirez AL, Reeck J, Maas CS: Botulinum toxin type B, 
(Myobloc) in the management of hyperkinetic facial lines. 
Otolaryngol Head Neck Surg 2002; 126:459-467.  
17) Alster TS, Lupton JR: Botulinum toxin type B, for dynamic 
glabellarrhytides refractory to botulinum toxin type 
A,DermatolSurg 2003; 29:516-518. 
18) Sadick NS: Prospective open-label study of botulinum toxin type B 
(Myobloc), at doses of 2,400 and 3,000 U for the treatment of 
glabellarwrinkles,DermatolSurg 2003; 29:501-507. 
19) Lowe N, Lask G, Yamauchi P. Efficacy and safety of botulinum 
toxins A and B, for the reduction of glabellarrhytids in female 
subjects, Presented at the American Academy of Dermatology 
2002 Winter Meeting; 2002 February 22-27; New Orleans, LA. 
20) Matarasso SL: Comparison of botulinum toxin types A and B, a 
bilateral and double-blind randomized evaluation in the treatment 
of canthalrhytides. DermatolSurg 2003; 29:7-13. 
21) Klein AW: Dilution and storage of botulinumtoxin,DermatolSurg 
1998; 24:1179-1180.  
22)  Huang W, Foster JA, Rogachefsky AS, Pharmacology of 
botulinum toxin. J Am AcadDermatol 2000; 43:249-259. 
23) Alam M, Dover JS, Arndt KA, Pain associated with injection of 
botulinumA exotoxin reconstituted using isotonic sodium chloride 
with and without preservative: a double-blind, randomized 
controlled trial. Arch Dermatol 2002; 138:510-514. 
24) Carruthers A, Carruthers J Dose dilution and duration of effect of 
botulinum toxin type A (BTX-A) for the treatment of 
glabellarrhytids, Presented at the American Academy of 
Dermatology 2002 Winter Meeting; 2002 February 22-27; New 
Orleans, LA. 
25) Lowe NJ: Botulinum toxin type A for facial rejuvenation: United 
States and United Kingdom perspectives,DermatolSurg 1998; 
24:1216-1218.  
26) Hexsel DM, Trindade de Almeida A, Rutowitsch M, et al: 
Multicenter, double-blind study of the efficacy of injections with 
botulinum toxin type A reconstituted up to six consecutive weeks 
before application,DermatolSurg 2003; 29:523-529.  
27) Flynn TC, Carruthers JA, Carruthers JDA: The use of the Ultra-
Fine II short needle 0.3-cc insulin syringe for botulinum toxin 
injections,J Am AcadDermatol 2002; 46:931-933. 
28) Carruthers J, Fagien S, Botox Consensus Group : Consensus 
recommendations on the use of botulinum toxin type A in facial 
aesthetics. PlastReconstrSurg 2004; 114(suppl):1S-22S. 
29) Smith KC, Comite SL, Balasubramanian S, Carver A, Liu 
JF,Vibrationanesthesia: a noninvasive method of reducing 
discomfort prior to dermatologic procedures,Dermatol Online J 
2004; 10:1. 
30) Carruthers JA, Lowe NJ, Menter MA, et al: A multicenter, double-
blind, randomized, placebo-controlled study of efficacy and safety 
of botulinum toxin type A, in the treatment of glabellarlines,J Am 
AcadDermatol 2002; 46:840-849. 
31) Carruthers JD, Lowe NJ, Menter MA, et al: Double-blind, placebo-
controlled study of the safety and efficacy of botulinum toxin type 
A, for patients with glabellar lines. PlastRecontrSurg 2003; 
112:1089-1098. 
32) Carruthers A, Carruthers J, Said S. Double-blind, randomized, 
parallel group, dose-ranging study of botulinum toxin type A in the 
treatment of glabellar lines, Presented at the European Academy of 
Dermatology and Venereology Meeting; 2001 October 10; 
Munich, Germany. 
33) Carruthers A, Carruthers J Botulinum toxin type A for treating 
glabellar lines in men: a dose ranging study, Presented at the 
Annual Meeting of the American Academy of Dermatology; 2003 
March 21-26; San Francisco, CA. 
34) Ahn MS, Catten M, Maas CS: Temporal brow lift using botulinum 
toxin A. Reconstruct Surg 2000; 105:1129-1135.  
35) Huang W, Rogachefsky AS, Foster, Brow lift with 
botulinumtoxin,DermatolSurg 2000; 26:55-60. 
36) Huilgol SC, Carruthers A, Carruthers JDA, Raising eyebrows with 
botulinumtoxin,DermatolSurg 2000; 25:373-376. 
37) Carruthers A, Said S. Botulinum toxin type A (BTX-A) in the 
treatment of glabellarrhytids: an objective analysis of treatment 
respons -. Presented - American Academy of Dermatology 2002 
Winter Meeting; 2002 February 22-27; New Orleans, LA. 
38) Carruthers A, Carruthers J- Glabella BTX-A injection and eyebrow 
height: a further photographic analysis. Presented- Annual Meeting 
of the American Academy of Dermatology; 2003 March 21-26; 
San Francisco, CA. 
39) Carruthers J, Carruthers A- BOTOX - in the mid and lower face 
and neck-SeminCutan Med Surg 2001; 20:85-92. 
40) Flynn TC, Carruthers J, Carruthers A -Botulinum-A toxin 
treatment of the lower eyelid improves infraorbitalrhytides and 
widens the eye - DermatolSurg 2001; 27:703-708.  
41)  Armstrong MWJ, Mountain RE, Murray JAM: Treatment of facial 
synkinesis and facial asymmetry with botulinum toxin type A 
following facial nerve palsy-ClinOtolaryngol Allied Sci 1996; 
21:15-22. 
42) Blitzer A, Brin MF, Keen MS, Aviv JE-Botulinum toxin, for the 
treatment of hyperfunctional lines of the face,ArchOtolaryngol 
Head Neck Surg 1993; 119:1018-1022.  
43) Borodic GE: Botulinum A toxin for (expressionistic) ptosis 
overcorrection after frontalissling,OphthalPlastReconstrSurg 1992; 
8:137-142.  
44) Carruthers A, Carruthers J: Clinical indications and injection 
technique for the cosmetic use of 
botulinumAexotoxin,DermatolSurg 1998; 24:1189-1194. 
45) Carruthers JDA, Carruthers JA: BotulinumA exotoxin in clinical 
ophthalmology,CanOphthalmol 1996; 31:389-400. 
46) To EW, Ahuja AT, Ho WS etalA- prospective study of the effect of 
botulinum toxin A, on masseteric muscle hypertrophy with 
ultrasonographic and electromyographic measurement. Br J 
PlastSurg 2001; 54:197-200.  
47) von Lindern JJ, Niederhagen B, Appel T, Berge S, Reich RH - 
Type A botulinum toxin for the treatment of hypertrophy of the 
masseter and temporal muscle: an alternative treatment - 
PlastReconstrSurg 2001; 107:327-332.  
48) Park MY, Ahn KY, Jung DS- Application of botulinum toxin A for 
treatment of facial contouring in the lower face. DermatolSurg 
2003; 29:477-483.  
49) Matarasso A, Matarasso SL, Brandt FS, Bellman B: BotulinumA 
exotoxin, in the management of platysma bands-PlastReconstrSurg 
1999; 103:645-652.  
50) Carruthers J, Carruthers A: Practical cosmetic Botox techniques, J 
Cutan Med Surg 1999; 3(suppl. 4):S49-S52. 
51) Fagien S: Botox for the treatment of dynamic and hyperkinetic 
facial lines and furrows - Adjunctive use in facial aesthetic surgery. 
PlastReconstrSurg 2003; 112:40S-52S.  
52) CarruthersJ,Zelichowska A: The power of combined therapies, 
Botox and ablative facial laser resurfacing - Am J CosmetSurg 
2000; 17:129-131.  
53) West TB, Alster TS-Effect of botulinum toxin type A,on 
movement-associated rhytides following CO2 laser resurfacing. 
DermatolSurg 1999; 25:259-261.  
54) Zimbler MS, Holds JB, Kokoska MS, et al: Effect of botulinum 
toxin pretreatment on laser resurfacing results: a prospective, 
randomized, blinded trial. Arch Facial PlastSurg 2001; 3:165-169.  
55) Lowe N, Lask G, Yamauchi P, Moore D, Patnaik R. Botulinum 
toxin type A (BTX-A) and ablative laser resurfacing (Erbium: 
YAG) - a comparison of efficacy and safety of combination 
therapy vs. ablative laser resurfacing alone for the treatment of 
crow's feet-Presented at the American Academy of Dermatology 
2002 Summer Meeting; 2002 July 31-August 4; New York, NY. 
56) Carruthers J-The effect of full-face broadband light treatments 
alone and in combination with bilateral crow's feet botulinum toxin 
type Achemodenervation. DermatolSurg 2004; 30:355. 
57) Carruthers J, Carruthers A, Maberley D- Deep resting 
glabellarrhytides, respond to BTX-A and HylanB,DermatolSurg 
2003; 29:539-544.  
58) Carruthers J, Carruthers A: A prospective, randomized, parallel 
group study,analyzing the effect of BTX-A (Botox) and nonanimal 
sourced hyaluronic acid (NASHA, Restylane) in combination 
compared with NASHA (Restylane) alone in severe 
glabellarrhytides in adult female subjects: treatment of severe 
glabellarrhytides with a hyaluronic acid derivative compared with 
the derivative BTX-A-DermatolSurg 2003; 29:802-809.  
59) Patel MP, Talmor M, Nolan WB: Botox and collagen for glabellar 
furrows: advantages of combination therapy-Ann PlastSurg 2004; 
52:442-447.  
60) Bushara KO, Jones JW, Park DM, Schutta HS-Botulinum toxin 
and sweating [abstr]-MovDisord 1995; 10:391. 
61) Lowe NJ, Yamauchi PS, Lask GP, Patnaik R, Iyer S- Efficacy and 
safety of botulinum toxin type A in the treatment of palmar 
hyperhidrosis: a double-blind, randomized, placebo-controlled 
study-DermatolSurg 2002; 28:822-827.  
62) Hurley-The eccrine sweat glands: structure and function. In: 
Freinkel RK, Woodley DT, ed-The Biology of the Skin, New 
York: Parthenon Publications; 2001:47-76. 
63)  Kenney LW, Munce TA: Aging and human temperature 
regulation-J ApplPhysiol 2003-95:2598-2603.  
64) Rothman S: Sweat secretion and Biochemistry Physiology of the 
Skin, Chicago-Chicago University Press- 1954:162-178.  
65) Sutton DR, Kowalski JW, Glaswer DA, Stang PE: US prevalence 
of hyperhidrosis and impact on individuals with axillary 
hyperhidrosis-results from a national survey-J Am AcadDermatol 
2004; 51:241-248.  
66) Hornberger J, Grimes K, Naumann M, et al: Recognition, diagnosis 
and treatment of primary focal hyperhidrosis-J Am AcadDermatol 
2004-51:274-286.  
67) Hurley HJ, Shelley WB: Axillary hyperhidrosis clinical features 
and local surgical management-Br J Dermatol 1966; 78:127-141. 
68) HigashimotoI,Yoshiura K, Hirakawa N, et al- Primary palmar 
hyperhidrosis locus maps to 14q11.2-q13, Am J Med Genet 2006; 
140:567-572. 
69) Masters W, Johnson V - Human Sexual Response, Boston: Little, 
Brown & Co.; 1966:287, 291. 
70) Schwartzman RJ, McLellan TL: Reflex sympathetic dystrophyA 
review. Arch Neurol 1987; 44:555-561.  
71) Linder F - Über den Einfluss der Hirnrinde auf die 
Schweissekretion (zurFrage der vegetativenHempilagie). Deutsche 
ZtschrNervenh 1947; 157:86-94. 
72) Prout BJ, Wardell WM: Sweating and peripheral blood flow in 
patients with pheochromocytoma - ClinSci 1969; 36:109-120.  
73) Sato K, Kang WH, Saga K, Sato KT - Biology of sweat glands and 
their disorders - Disorders of sweat gland function. J Am 
AcadDermatol 1999; 20:713-726.  
74) Mailander JC - Heritable gustatory sweating. J Am Med Assoc 
1967; 201:203-205. 
75) Mellinkoff J, Mellinkoff JL - Gustatory sweating of the left knee ,J 
Am Med Assoc 1950; 142:901-902.  
76) Bloor K: Gustatory sweating and other responses after cervico-
thoracic sympathectomy. Brain 1969; 92:137-146. 
77) Pasquina RF, Houston RM, Belandres PV - Beta-blockade in the 
treatment of autonomic dysreflexiaA case report and review, Arch 
Phys Med Rehab 1998; 79:582-584.  
78) Hokfelt T, Johansson O, Kellerth JO, et al: Immunohistochemical 
distribution of substance P. In - vonEuler US, Pernow B, ed. 
Substance P, New York -Raven Press; 1977:117-145.  
79) Randall WC: Quantitation of the output of individual sweat glands 
and their response to stimulation,J ApplPhysiol1949; 2:72-80. 
80) LeWitt P: Hyperhidrosis and hypothermia responsive to 
oxybutynin,Neurology 1998; 39:506-507.  
81) Edick CM: Oral glycopyrrolate for the treatment of diabetic 
gustatory sweating,AnnPharmacother 2005; 39:1760.  
82) Torch EM: Remission of facial and scalp hyperhidrosis with 
clonidine hydrochloride and topical aluminum chloride. South Med 
J 2000; 93:68-69. 
83) Manusov EG, Nadeau MT: Hyperhidrosis: a management 
dilemma. J FamPract 1989; 28:412-415.  
84) Connolly M, de Berker D: Management of primary hyperhidrosis: 
a summary of the different treatment modalities - Am J 
ClinDermatol 2003; 4:861-897. 
  
 
 
 
 
 
INRODUCTION 
  
 
 
 
 
 
AIM OF THE 
STUDY 
  
 
 
 
 
REVIEW OF 
LITERATURE 
  
 
 
 
 
MATERIALS AND 
METHODS 
  
 
 
 
 
 
RESULTS 
  
 
 
 
 
 
DISCUSSION 
  
 
 
 
 
 
CONCLUSION 
  
 
 
 
 
 
BIBLIOGRAPHY 
 
 
 
  
 
ANNEXURES 
 
 
 
PROFORMA 
Name     Age    Sex 
Skin O.P No: 
Occupation: 
Address: 
Per capita income: 
Presenting complaints: 
H/O present illness : 
 Onset 
 Duration 
 Course 
 H/O associated symptoms 
 H/O predisposing factors 
 H/O aggravating/relieving factors 
 H/O abdominal distension/mass/pain 
 H/O other systemic disturbances 
Past history: 
 H/O any major medical/surgical illness 
Family history: 
Personal history: 
 Diet: 
 Sleep: 
 Appetite: 
 Bowel & bladder habits: 
 Habits: smoking/alcoholism 
Menstrual history (in females): 
 Menarche/menopause; cycles; flow 
Obstetric history (in females): 
 H/O pregnancy/lactation 
Treatment history: 
 H/O previous treatment / surgeries 
 H/O allergy to botox 
General physical examination: 
 Consciousness; orientation 
 Built & nourishment 
 Febrile/afebrile 
 Pallor/cyanosis/clubbing/icterus/lymphadenopathy/pedal edema 
 Pulse rate:    Peripheral pulses: 
 Blood pressure: 
 Respiratory rate: 
 Temperature: 
Systemic examination: 
 Cardiovascular system: 
 Respiratory system: 
 Abdomen: 
 Central nervous system: 
  
Local examination: 
I HYPERHIDROSIS: 
 Inspection – sites of involvement , skin over the sites 
II WRINKLES: 
 Inspection – sites involved, type of wrinkles , skin over the face 
Clinical test –  
Minors starch iodine test – assess and document severity 
Hyperhidrosis severity score system – subjective assessment 
Photographic recording – pre & post procedure  
DIAGNOSIS: 
INVESTIGATIONS: 
 Hb%, TC, DC, ESR , Platelet 
 Urine – albumin, sugar, deposits 
 BT, CT 
 Thyroid profile 
 
BOTOULINUM TOXIN VIAL 
 
PROCEDURE TRAY 
 
  
 
 
DURING PROCEDURE - HYPERHIDROSIS 
 
  
DURING PROCEDURE - WRINKLES 
 
 
 
PALMAR HYPERHIDROSISBEFORE TREATMENT 
RIGHT HAND TO BE TREATED 
 
COMPLETE RESPONSE AFTER TREATMENT 
 
 
PALMAR HYPERHIDROSISBEFORE TREATMENT 
LEFTHAND TO BE TREATED 
 
PARTIAL RESPONSE AFTER TREATMENT 
 
CROWS FEET – BEFORE TREATMENT 
 
COMPLETE RESPONSE AFTER TREATMENT 
 
CROWS FEET – BEFORE TREATMENT 
 
 
COMPLETE RESPONSE AFTER TREATMENT 
 
CROWS FEET – BEFORE TREATMENT 
 
COMPLETE RESPONSE AFTER TREATMENT 
 
CROWS FEET – BEFORE TREATMENT 
 
  
COMPLETE RESPONSE AFTER TREATMENT 
 
 
CROWS FEET – BEFORE TREATMENT 
 
  
PARTIAL RESPONSE AFTER TREATMENT 
 
 
MARKING FOR FOREHEAD WRINKLES 
 
 
IMMEDIATE POST PROCEDURE 
 
 
 
  
 
 
COMPLICATION - HEMATOMA 
 
 
MASTER CHART – HYPERHIDROSIS 
 
S.NO NAME AGE SEX HEMOGRAM BT CT THYROID PROFILE 
REPSONSE TO 
TREATMENT 
OVERALL SATISFACTION 
WITH TREATMENT 
1. MURALI 32 M WNL 2’ 10’’ 4’ 27’’ WNL COMPLETE GOOD 
2. KARTHIK 29 M WNL 3’ 06’’ 5’ 01’’ WNL COMPLETE GOOD 
3. SHALINI 18 F WNL 2’ 12’’ 6’ 11’’ WNL COMPLETE GOOD 
4. MALAR 26 F WNL 2’ 16’’ 4’ 31’’ WNL PARTIAL FAIR 
5. ESTHER 35 F WNL 3’ 10’’ 4’ 43’’ WNL COMPLETE GOOD 
6. MARIAMMA 27 F WNL 4’ 00’’ 4’ 34’’ WNL COMPLETE GOOD 
7. KANCHANA 19 F WNL 2’ 17’’ 5’ 21’’ WNL COMPLETE GOOD 
8. MARY 22 F WNL 2’ 07’’ 6’ 17’’ WNL COMPLETE GOOD 
9. RAVI 38 M WNL 2’ 14’’ 4’ 11’’ WNL COMPLETE GOOD 
10. MANIMEGALAI 25 F WNL 3’ 18’’ 4’ 23’’ WNL COMPLETE GOOD 
11. RANI 21 F WNL 4’ 02’’ 4’ 45’’ WNL COMPLETE GOOD 
12. SHOBANA 22 F WNL 3’ 15’’ 5’ 29’’ WNL COMPLETE GOOD 
13. NITHYA 20 F WNL 2’ 19’’ 4’ 11’’ WNL PARTIAL FAIR 
14. POOJA 19 F WNL 2’ 34’’ 5’ 21’’ WNL COMPLETE GOOD 
15. SHANKAR 19 M WNL 2’ 17’’ 4’ 35’’ WNL COMPLETE GOOD 
16. SENTHAMIL 29 F WNL 3’ 10’’ 4’ 23’’ WNL COMPLETE GOOD 
17. SELVI 22 F WNL 4’ 19’’ 6’ 00’’ WNL COMPLETE GOOD 
18. VALAVAN 23 M WNL 2’ 13’’ 4’ 20’’ WNL COMPLETE GOOD 
19. ERUSAMMA 31 F WNL 2’ 15’’ 4’ 15’’ WNL COMPLETE GOOD 
20. CHITRA 41 F WNL 2’ 15’’ 5’ 11’’ WNL COMPLETE GOOD 
  
      MASTER CHART – WRINKLES 
S.NO NAME AGE SEX HEMOGRAM BT CT REPSONSE TO TREATMENT 
OVERALL SATISFACTION WITH 
TREATMENT 
1. SANDHYA 32 F WNL 2’ 10’’ 4’ 27’’ COMPLETE GOOD 
2. MANI 29 M WNL 3’ 06’’ 5’ 01’’ COMPLETE GOOD 
3. SHARADHA 55 F WNL 2’ 12’’ 6’ 11’’ COMPLETE GOOD 
4. LEELA 26 F WNL 2’ 16’’ 4’ 31’’ PARTIAL FAIR 
5. SHANKARI 35 F WNL 3’ 10’’ 4’ 43’’ COMPLETE GOOD 
6. YOGESHWARI 27 F WNL 4’ 00’’ 4’ 34’’ COMPLETE GOOD 
7. THARANI 39 F WNL 2’ 17’’ 5’ 21’’ COMPLETE GOOD 
8. POORANI 59 F WNL 2’ 07’’ 6’ 17’’ COMPLETE GOOD 
9. BABA 38 M WNL 2’ 14’’ 4’ 11’’ COMPLETE GOOD 
10. HARINI 35 F WNL 3’ 18’’ 4’ 23’’ COMPLETE GOOD 
 
  
